» Articles » PMID: 39684352

High- and Moderate-Risk Variants Among Breast Cancer Patients and Healthy Donors Enrolled in Multigene Panel Testing in a Population of Central Russia

Abstract

Assessments of breast cancer (BC) risk in carriers of pathogenic variants identified by gene panel testing in different populations are highly in demand worldwide. We performed target sequencing of 78 genes involved in DNA repair in 860 females with BC and 520 age- and family history-matched controls from Central Russia. Among BC patients, 562/860 (65.3%) were aged 50 years or less at the time of diagnosis. In total, 190/860 (22%) BC patients were carriers of 198 pathogenic/likely pathogenic (P/LP) variants in 30 genes, while among controls, 32/520 (6.2%) carriers of P/LP variants in 17 genes were identified. The odds ratio [95% confidence interval] was 16.3 [4.0-66.7] for ; 12.0 [2.9-45.9] for ; and 7.3 [0.9-56.7] for ( < 0.05). Previously undescribed and variants, as well as novel recurrent mutations, were identified. The contribution to BC susceptibility of truncating variants in the genes , , , (p. E1155*), and (p. P32fs) was evaluated. The , , and genes did not demonstrate associations with BC risk. Finding deleterious mutations in BC patients is important for diagnosis and management; in controls, it opens up the possibility of prevention and early diagnostics.

References
1.
Fang C, Wu H, Zhang M, Liu J, Zhang G . Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. Front Cell Dev Biol. 2020; 8:160. PMC: 7142266. DOI: 10.3389/fcell.2020.00160. View

2.
Rump A, Benet-Pages A, Schubert S, Kuhlmann J, Janavicius R, Machackova E . Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer. PLoS Genet. 2016; 12(8):e1006248. PMC: 4978395. DOI: 10.1371/journal.pgen.1006248. View

3.
Marabelli M, Cheng S, Parmigiani G . Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk. Genet Epidemiol. 2016; 40(5):425-31. PMC: 7376952. DOI: 10.1002/gepi.21971. View

4.
Tung N, Lin N, Kidd J, Allen B, Singh N, Wenstrup R . Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016; 34(13):1460-8. PMC: 4872307. DOI: 10.1200/JCO.2015.65.0747. View

5.
Kechin A, Boyarskikh U, Barinov A, Tanas A, Kazakova S, Zhevlova A . A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia. Breast Cancer Res Treat. 2022; 197(2):387-395. DOI: 10.1007/s10549-022-06782-2. View